An estimated 13,000 women will die of the disease in 2022. While most patients initially respond to treatment the majority will recur. While there have been strides made in the treatment of this disease, specifically in patients whose tumors harbor BRCA mutations or those that are BRCA-wt and have defective DNA repair (HRD) [22-24], there remains no specific treatment for patients with intact DNA repair (HRP). Vigil is a personalized immunotherapy [18, 19] that is made from the patient's own tumor. DNA is introduced into the tumor cells to promote an effective immune response against the cancer. The cells are irradiated so they are unable to replicate but are used to educate the immune syst...

Read More

An estimated 13,000 women will die of the disease in 2022. While most patients initially respond to treatment the majority will recur. While there have been strides made in the treatment of this disease, specifically in patients whose tumors harbor BRCA mutations or those that are BRCA-wt and have defective DNA repair (HRD) [22-24], there remains no specific treatment for patients with intact DNA repair (HRP). Vigil is a personalized immunotherapy [18, 19] that is made from the patient's own tumor. DNA is introduced into the tumor cells to promote an effective immune response against the cancer. The cells are irradiated so they are unable to replicate but are used to educate the immune system on what the cancer looks like. Vigil is injected into the skin of the patient once every 3 weeks. Previous work has shown Vigil is well tolerated and demonstrates activity in multiple different cancer types. This Phase 2 clinical trial will enroll women with platinum sensitive recurrent HRP OC who have a CR after surgery and chemotherapy. Their cancer must be BRCA-wt and have the ability to perform DNA repair (HRP). The trial will investigate Vigil in combination with bev compared to Vigil placebo/bev. Bev is used as maintenance treatment for OC but has limited efficacy as a monotherapy. We previously showed significant improvement in relapse free and OS with Vigil in OC patients with HRP type tumors.

Read Less